Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
A 324.69 1.48% 4.72
ARGX closed up 1.48 percent on Friday, May 20, 2022, on 85 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Overbought Stochastic Strength 0.00%
Crossed Above 50 DMA Bullish 1.48%
MACD Bullish Centerline Cross Bullish 1.48%
180 Bullish Setup Bullish Swing Setup 1.48%
Gapped Up Strength 1.48%
Fell Below 50 DMA Bearish 6.56%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.56%
200 DMA Support Bullish 6.56%
Outside Day Range Expansion 6.56%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 19 hours ago
Bullish 180 Entry about 19 hours ago
Rose Above Previous Day's High about 19 hours ago
2x Volume Pace about 19 hours ago
1.5x Volume Pace about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

argenx SE Description

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Disease Cancer Immunotherapy Inflammation Lymphoma Acute Myeloid Leukemia Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Dyslipidemia Hematological Cancers Myasthenia Myasthenia Gravis Thrombocytopenia Janus Kinase Inhibitor Skin Inflammation Treatment Of Hematological Cancers Rgx Tolerx

Is ARGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 356.78
52 Week Low 249.5
Average Volume 298,644
200-Day Moving Average 304.58
50-Day Moving Average 308.19
20-Day Moving Average 301.91
10-Day Moving Average 302.94
Average True Range 15.41
RSI 56.71
ADX 16.59
+DI 22.02
-DI 24.30
Chandelier Exit (Long, 3 ATRs) 280.78
Chandelier Exit (Short, 3 ATRs) 313.65
Upper Bollinger Bands 331.17
Lower Bollinger Band 272.64
Percent B (%b) 0.89
BandWidth 19.39
MACD Line 2.05
MACD Signal Line -0.99
MACD Histogram 3.04
Fundamentals Value
Market Cap 15.3 Billion
Num Shares 47.1 Million
EPS -1.73
Price-to-Earnings (P/E) Ratio -188.23
Price-to-Sales 193.85
Price-to-Book 6.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 339.74
Resistance 3 (R3) 338.31 331.88 337.23
Resistance 2 (R2) 331.88 328.05 332.59 336.39
Resistance 1 (R1) 328.28 325.68 330.08 329.71 335.56
Pivot Point 321.85 321.85 322.75 322.56 321.85
Support 1 (S1) 318.25 318.02 320.05 319.68 313.82
Support 2 (S2) 311.82 315.65 312.53 312.99
Support 3 (S3) 308.22 311.82 312.15
Support 4 (S4) 309.65